1 March 2025 Pathology Changes - Amendment of MBS items 73296 and 73297 for BRCA-related breast, ovarian, fallopian tube or primary peritoneal cancer due to family history

From 1 March 2025, the Government is making minor amendments to Medicare Benefits Schedule (MBS) items 73296 and 73297. MBS items 73296 and 73297 are relevant to patients at a greater risk of BRCA-related breast, ovarian, fallopian tube, or primary peritoneal cancer due to family history. The amendments will enable clinicians to select the most appropriate genes for testing, in addition to BRCA 1 and 2. Prior to the changes, MBS items 73296 and 73297 only supported testing in specified genes (STK11, PTEN, CDH1, PALB2 and TP53) in addition to BRCA 1 and 2.

These amended items remain relevant for specialists, consultant physicians and pathologists who manage patients who are at a greater risk of these cancers.

Further information is provided in the Factsheet below:
Word Version - Amendment of MBS items 73296 and 73297 for BRCA and other relevant genetic variant testing in patients at a greater risk of BRCA-related breast, ovarian, fallopian tube or primary peritoneal cancer due to family history (Word 130 KB)
PDF Version - Amendment of MBS items 73296 and 73297 for BRCA and other relevant genetic variant testing in patients at a greater risk of BRCA-related breast, ovarian, fallopian tube or primary peritoneal cancer due to family history (PDF 213 KB)